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ANALYSIS OF FREE ANALYTE FRACTIONS 
BY RAPIDAFFINITY CHROMATOGRAPHY 
REFERENCE TO RELATED APPLICATIONS 
This application is a continuation-in-part of U.S. Ser. No. 
09/776,800 filed on Feb. 5, 2001, now pending, which is 
hereby incorporated by reference in its entirety. 
This invention was made with Government support under 
Grant No. 5 RO1 GMO44931 awarded by the National 
Institute of General Medical Sciences. The Government has 
certain rights in this invention. 
FIELD OF THE INVENTION 
The invention is directed toward an analytical method to 
determine the concentration of the free analyte fraction in a 
Sample. More particularly, the method encompasses the use 
of affinity chromatography to determine the concentration of 
the free analyte fraction in a Sample. 
BACKGROUND OF THE INVENTION 
Many drugs, hormones, and toxins exist in two distinct 
forms as they pass through the blood stream: 1) a fraction 
that is non-covalently bound to proteins or other blood 
components and 2) a fraction that is non-bound, or free, in 
Solution. The free and bound fractions are present in a 
dynamic State, in which Solutes in one State are continually 
eXchanging with those in the other. Accordingly, in biologi 
cal Systems this proceSS is constant and an equilibrium is 
formed between the free and bound fractions. 
It has long been hypothesized that the free fraction of such 
Substances is the biologically-active form, Since it is this 
form which crosses cell membranes and interacts with cell 
receptors or other target ligands. Because the free fraction is 
the biologically-active form, this makes analysis of free 
fractions of these Substances of particular interest in clinical 
chemistry and pharmaceutical Science as a means for con 
trolling and studying their effects within the body. 
For many Substances it is possible to use their total 
concentrations in blood or Serum as estimates of their free 
levels by assuming there is a constant relationship between 
these two types of values. However, there are numerous 
Situations where this approach does not provide meaningful, 
or even remotely accurate information. For example, after 
Surgery, during malnutrition or pregnancy, and in various 
disease states (e.g., cancer, renal failure or liver disease) 
there can be a large fluctuation in the concentration of 
binding proteins present in blood. This can Shift the equi 
librium between these proteins and drugs that bind to them 
and concomitantly cause a change in a drugs free fraction 
even though its total concentration remains unaffected. 
Similar shifts in drug-protein binding can occur with age 
(e.g., in newborns or the elderly) and in situations where 
Several drugs and/or endogenous agents compete for the 
Same binding proteins. A drug with a high total concentra 
tion versus its binding proteins also createS problems when 
trying to estimate the free fraction based upon total protein 
concentrations Since this may result in a non-linear relation 
ship between the drugs total and free levels. 
Although Several analytical methods have been developed 
in an attempt to determine the free fraction, all of these 
methods are plagued with inherent inaccuracies or are 
lengthy and tedious to perform. Examples of these methods 
include equilibrium dialysis, ultrafiltration and the use of 
natural filtrates, Such as tears or Saliva. A major problem 












use of an additional binding reagent or Separation proceSS 
that interacts with the free or bound fraction and causes the 
equilibrium between these fractions to be altered. For 
example, techniques with long analysis times, on the order 
of Several Seconds, results in bias in the measurement 
process because it allows the release of a significant amount 
of Solutes from the bound fraction which is then detected 
with the original free fraction. The end result is an error in 
the apparent concentration of free fraction that is measured. 
In addition, many of these techniques Suffer from non 
Specific interactions (e.g., binding of drugs to dialysis or 
filtration membranes), and are limited to only certain types 
of analytes (as is the case with natural filtrates). 
Accordingly, a need exists to determine the free fraction 
without impacting the equilibrium between the free and 
bound fractions of the Solutes. Equally, a need exists for a 
method that is highly specific and can be employed to 
determine the free fraction of a vast number of different 
Substances. 
SUMMARY OF THE INVENTION 
Among the Several aspects of the invention therefore, is 
provided a method to determine the concentration of a free 
analyte fraction in a Sample, the Sample comprising a bound 
analyte fraction and the free analyte fraction, the method 
comprising applying the Sample to an affinity column 
wherein the column Separates the free analyte fraction from 
the Sample in the millisecond time domain, detection of 
Signal from the free analyte fraction Separated from the 
Sample, and determining the concentration of free analyte 
present in the Sample. 
In yet another aspect of the invention is provided a 
method to determine the concentration of a free analyte 
fraction in a Sample, the Sample comprising a bound analyte 
fraction and a free analyte fraction, the method comprising 
applying the Sample to an affinity column, the column 
Separating the Sample into the free analyte fraction and the 
bound analyte fraction in the millisecond time domain 
wherein the free analyte fraction is adsorbed to the column 
and the bound analyte fraction passes through the column, 
applying a Series of Standards to the affinity column wherein 
each Standard applied comprises a known concentration of 
the Same free analyte present in the Sample, the column 
Separating each of the Standards into a free fraction and a 
bound fraction in the millisecond time domain wherein the 
free fraction is adsorbed to the column and the bound 
fraction passes through the column, detection of Signal from 
the free analyte fraction Separated from the sample in (a) 
above, detection of Signal from the free analyte fraction 
Separated from the standard in (b) above, generating a 
calibration curve based upon the signal detected in (d) 
above, the curve comprising a graph of the concentration of 
free analyte present in each Standard Versus the Signal 
detected for each concentration, and determining the con 
centration of the free analyte fraction present in the Sample 
by comparing the Signal detected in (c) above with the 
calibration curve in (e) above. 
Yet a further aspect of the invention provides a method to 
determine the concentration of a free analyte fraction in a 
Sample, the Sample comprising a bound analyte fraction and 
a free analyte fraction, the method comprising applying the 
Sample to an affinity column, the column Separating the 
Sample into the free analyte fraction and the bound analyte 
fraction in the millisecond time domain wherein the free 
analyte fraction is adsorbed to the column and the bound 
analyte fraction passes through the column, applying the 
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Sample set forth in (a) to an inert control column wherein the 
free analyte fraction does not adsorb to the column and a 
total analyte fraction comprising the free analyte fraction 
and the bound analyte fraction passes through the column, 
applying a Series of Standards to the affinity column wherein 
each Standard applied comprises a known concentration of 
the same analyte present in the Sample, the column Separat 
ing each of the Standards into a free fraction and a bound 
fraction in the millisecond time domain wherein the free 
fraction is adsorbed to the column and the bound fraction 
passes through the column, applying the Same Series of 
Standards set forth in (c) to an inert control column wherein 
the free analyte fraction does not adsorb to the column and 
a total analyte fraction comprising the free analyte fraction 
and the bound analyte fraction passes through the column, 
detection of Signal from the bound analyte fraction of the 
Sample in (a) above, detection of signal from the total 
analyte fraction of the sample in (b) above, detection of 
Signal from the bound fraction of the Standard in (c) above, 
detection of Signal from the total analyte fraction of the 
Standard in (d) above, generating a calibration curve based 
upon the signal detected in (g) above, the curve comprising 
a graph of the bound concentration of analyte present in each 
Standard versus the Signal detected for each concentration, 
generating a calibration curve based upon the Signal detected 
in (h) above, the curve comprising a graph of the total 
concentration of analyte present in each Standard Versus the 
Signal detected for each concentration, determining the 
bound analyte fraction in the Samples by comparing the 
Signal in (e) above with the calibration curve in (i) above, 
determining the total analyte fraction in the Samples by 
comparing the Signal in (f) above with the calibration curve 
in () above, and determining the concentration of the free 
analyte fraction present in the Sample by Subtracting the 
bound analyte fraction in (k) above from the total analyte 
fraction in (1) above. 
Still another aspect of the invention provides a method to 
determine the concentration of a free analyte fraction in a 
Sample, the Sample comprising a bound analyte fraction and 
the free analyte fraction, the method comprising applying 
the Sample to an affinity column wherein the column Sepa 
rates the free analyte fraction from the Sample in the 
millisecond time domain, detection of Signal from the free 
analyte fraction Separated from the Sample and comparing 
the signal detected in (b) to a standard thereby determining 
the concentration of free analyte present in the sample. 
BRIEF DESCRIPTION OF THE DRAWINGS 
These and other features, aspects, and advantages of the 
present invention will become better understood with regard 
to the following description, appended claims and accom 
panying figures where: 
FIG. 1 depicts a drawing of a typical microcolumn that 
may be employed in the method of the invention. 
FIG. 2 depicts change in column Void time with column 
length and solvent flow rate for 2 mm ID HPLC columns 
packed with porous Silica. These results assume an overall 
porosity of 0.80 within the column (i.e., 80% of the column 
Volume is occupied by the mobile phase). Using a column 
with an inner diameter of 1 mm or 4 mm gives Similar results 
but with the vertical position of-the lines in this graph being 
lowered or raised by 4-fold, respectively. 
FIG. 3 depicts the reproducibility of stationary phase 
content in a Sandwich microcolumn as a function of the 
number of injections which were used to apply a fixed 











IDX620 um microcolumn. These results represent the aver 
age of triplicate analyses. 
FIG. 4 depicts release of protein-bound S-warfarin fol 
lowing the instantaneous removal of this drugs free fraction 
from an equilibrium mixture of S-warfarin and HSA. The 
graph in (a) shows the progression of this reaction over ten 
Seconds, while the plot in (b) shows an expanded view on the 
Sub-Second time Scale. These graphs were generated for a 
starting mixture that contained 4.56x10 M HSA and 
1.1x10 MS-warfarin at 25°C. An equilibrium constant of 
3.4x10M was used to determine the initial amount of free 
warfarin in this sample. A first-order rate constant of 0.14s' 
was used to describe the dissociation of S-warfarin from 
HSA 
FIG. 5 depicts chromatograms for the injection of a 20 u, 
sample of 8x107M R-warfarin onto (a) a diol-bonded silica 
column and (b) an anti-warfarin immunoaffinity column at a 
flow rate of 3.0 mL/min (effective column residence time, 60 
ms). Other experimental conditions are provided in the 
Materials and Methods of the Example section. 
FIG. 6 depicts a Schematic of a chromatographic System 
for the extraction and measurement of free and protein 
bound warfarin. Details on the construction of this system 
can be found in the Materials and Methods of the Example 
Section. 
FIG. 7 depicts a chromatogram for separation of HSA 
from R-warfarin after the passage of these compounds as a 
mixture through an anti-warfarin immunoaffinity microcol 
umn. The initial sample contained 1.1x10 M R-warfarin 
and 4.5x10-5 MHSA. Other conditions are provided in the 
teXt. 
FIG. 8 depicts simulated extraction of free warfarin from 
a mixture of R-warfarin and HSA. The sample and column 
conditions used in generating this plot were the same as 
those that were present for the experimental results in FIG. 
7. The Solid bottom line indicates the relative amount of free 
warfarin that was extracted in the absence of HSA. The Solid 
top line shows the amount of warfarin that was extracted 
from warfarin/HSA mixtures when the bound warfarin was 
allowed to dissociate from and rebind to HSA as the sample 
passed through the column. The dashed line is shown for 
reference and represents a case in which the amount of 
extracted warfarin was identical to the amount of free 
warfarin in the injected Samples. These Simulations were 
based on association and dissociation rate constants of 
1x10 M S and 0.4 s' for the interactions of 
R-warfarin with HSA at 25 C. The adsorption of warfarin 
to the immunoaffinity column was described by using a 
column binding capacity of 5x10' mol and a second-order 
association rate constant of 1x10 M S '. 
Abbreviations and Definitions 
To facilitate understanding of the invention, a number of 
terms and abbreviations as used herein are defined below: 
“Analyte' or “Target Analyte” are used interchangeably 
herein, and shall mean the component of the Sample that 
binds to the binding agent present in the active layer of the 
microcolumn. The analyte will typically comprise the free 
fraction of a drug, hormone, toxin, metal ion, fatty acid, 
bilirubin or any other endogenous or exogenous compound. 
Additionally, the analyte may also comprise any other 
inorganic or organic compound capable of being Separated 
from the Sample, as described herein. 
“Binding Agent', as utilized herein, shall mean the agent 
in the active layer capable of Selectively binding the target 
analyte. 
“Binding Compound”, as utilized herein, shall mean the 
compound that the bound fraction binds. Typically, the 
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binding compound comprises a protein, cell or any other 
endogenous or exogenous compound. 
“Bound Fraction” or “Bound Analyte Fraction” are used 
interchangeably herein, and shall mean the portion of the 
analyte which is bound to a binding compound. 
“Free Fraction” or “Free Analyte Fraction” are used 
interchangeably herein, and shall mean the portion of the 
analyte which is not bound to a binding compound. 
"Millisecond Time Domain', as utilized herein, shall 
mean any amount of time less than one Second. 
"Sandwich microcolumn', as utilized herein, Shall mean 
an embodiment of the invention wherein the microcolumn 
contains a top inert layer, a bottom inert layer and an active 
layer between the two inert layers. 
“Sample” or “Liquid” are used interchangeably herein 
and shall mean the mixture applied to the microcolumn 
containing the analyte. In addition to the analyte, the Sample 
(liquid) generally also contains a loading buffer. Any loading 
buffer may be employed to the extent that the buffer does not 
interfere with the Separation process. The Sample may 
comprise any mixture with an analyte. Typically, however, 
the Sample will be comprised of a biological fluid Such as 
blood, plasma, urine, cerebroSpinal fluid, tissue samples, or 
intracellular fluid. 
“Uniform Manner”, as utilized herein, shall mean loading 
the layers of the microcolumn in a manner Such that these 
layerS have a Substantially equal distribution of Support in 
both a horizontal and vertical direction. 
BSA=Bovine Serum Albumin 
FPLC=Fast-Protein Liquid Chromatography 
HPLC=High-Performance Liquid Chromatography 
Description of the Preferred Embodiments 
Many compounds, as Stated above, exist in two distinct 
forms as they pass through the blood stream: 1) a fraction 
that is non-covalently bound to proteins or other binding 
compounds and 2) a fraction that is non-bound, or free, in 
Solution. The free and bound fractions are present in a 
dynamic State, in which Solutes in one State are continually 
eXchanging with those in the other. Applicants have discov 
ered a method to accurately determine the free analyte 
fraction of a Sample comprising a free analyte fraction and 
a bound analyte fraction. The method of the present inven 
tion employs the use of affinity microcolumns to extract the 
free fraction of an analyte from the Sample in the millisecond 
time domain. The capability of extracting the free fraction in 
this time domain allows the free fraction to be separated 
without impacting the equilibrium between the free and 
bound fractions. Applicants discovery, accordingly, circum 
vents a major problem associated with the long Separation 
times that plague current detection techniques. Upon its 
Separation, the concentration of the free fraction is then 
determined employing Standard analytical methods. 
I. Affinity Microcolumn Design and Construction 
The method of the present invention employs the use of 
a microcolumn to Separate the free fraction of an analyte 
from the Sample in the millisecond time domain. AS utilized 
herein, the terms “microcolumn” or “column” are used 
interchangeably and FIG. 1 depicts a typical microcolumn 
that may be employed in the method of the invention. As 
shown in FIG. 1, the microcolumn 1 generally has a tubular 
configuration with a first end 2, a Second end 3, a passage 
way 4 there between, and a retaining means at the first 5 and 
Second ends 6 of the microcolumn 1. However, the micro 
column 1 may comprise any number of different shapes, all 
of which are embodiments of the present invention. The 











pore material that acts to hold the Support particles within 
the column while allowing fluid flow there through. The 
microcolumn 1 may also contain end fittings at the first 7 and 
Second 8 ends of the microcolumn 1 used to connect the 
column to the chromatographic System. The microcolumn 1 
comprises a thin active layer 9 to facilitate Separation of the 
analyte from the Sample in the millisecond time Scale and 
typically a Single inert layer in one embodiment, to Several 
inert layers in additional embodiments. FIG. 1 illustrates an 
embodiment with a top inert layer 10 and a bottom inert 
layer 11. 
A Salient feature of the current invention is the capability 
of removing a significant amount of the free fraction of a 
particular analyte from a Sample without release of the 
analyte from its protein-bound fraction. In order to accom 
plish this task, as delineated above, the extraction process is 
preferably accomplished in the millisecond time domain. 
The microcolumn design described herein is particularly 
Suitable for this application because, due in part to its 
relatively thin active layer, it can extract the free fraction 
within this time range. AS utilized herein, “length' of a layer 
means the thickness or width of the layer. As illustrated by 
FIG. 2 (plot derived by calculation), only columns with 
active layer lengths in the range of about 100 microns to 
about 1 millimeter allow Separation in the millisecond time 
domain when employing standard HPLC flow rates of about 
0.1 to about 1.0 mL/min. Accordingly, to achieve Separation 
in this time range, the microcolumns employed generally 
comprise an active layer that may be less than about 10 
microns in thickness. Typically, however, the active layer is 
from about 10 microns to about 1.1 millimeters in thickness 
and preferably, is not less than approximately 60 microns in 
thickness. Applicants have found that active layers with 
these dimensions, depending upon the Specific Sample 
applied, are generally capable of extracting an analyte in 
about 1 to about 500 milliseconds. And, more preferably, in 
less than about 200 milliseconds. 
In addition to rapid extraction of the free fraction, an 
additional salient feature is the ability of the active layer to 
bind the target analyte with both a high degree of Selectivity 
and with a relatively high binding affinity. The active layer, 
therefore, typically is comprised of Support particles deriva 
tized with any binding agent possessing Selectivity and 
having a high binding affinity for the target analyte. 
Preferably, such binding affinity is from about 10° to about 
10 M' or greater. In a preferred embodiment, the binding 
agents are antibodies raised against the target analyte. The 
antibodies can be either monoclonal or polyclonal. 
However, monoclonal antibodies are generally employed in 
applications where a higher degree of Selectivity is desired 
and polyclonals are more typically utilized in applications 
where a higher degree of binding 35 affinity is desired. 
Examples of other Suitable binding agents include nucleic 
acid ligands (e.g. aptamers), Synthetic molecular imprints, 
antibody fragments (e.g. Fab fragments), antibody related 
molecules (e.g. chimeras or F, chain fragments), and 
recombinant proteins that act as antibody mimics. The 
binding agent, once Selected, may be isolated in accordance 
with any generally known method. 
The binding agent can be derivatized to the Support 
particles by any method generally known in the art. 
However, the method preferably immobilizes the binding 
agent to the Support particle in a manner Such that a 
relatively high percent of the binding agent is active (i.e. 
binds the target analyte) after the immobilization process. 
Suitable immobilization methods for protein ligands, for 
example, include the Schiff base method and the carbonyl 
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diimidazole method. The Schiff base method is generally 
employed when immobilizing the binding agent through free 
amine groups. 
However, when the binding agent comprises antibodies, 
applicants have found that a more preferred approach is 
immobilization through the antibodies carbohydrate region 
because this generally results in an active layer with a higher 
number of active binding Sites compared to when immobi 
lization is performed through free amine groups. Any 
method known in the art for immobilization via carbohy 
drate regions may be employed. 
Additionally, the Overall binding capacity of the micro 
column is also an important feature because it impacts both 
the time and efficiency of extraction by the active layer. The 
binding capacity of the column, in part, is determined by the 
number of active binding siteS present in the active layer. 
Preferably, the minimum number of active binding sites in 
the column comprises a ratio of active binding Sites to free 
analyte not leSS than about 1:1, and even more preferably, 
not less than about 10:1. However, still more preferably, 
Support particles in the active layer will be derivatized with 
the maximum concentration of active binding agent achiev 
able So that the column has the largest binding capacity 
possible. 
The active layer, additionally, may comprise a number of 
different Support particles. The Support particles, as detailed 
above, function primarily as a Surface to immobilize the 
binding agent. The diameter of the particle, however, is an 
important feature that should be considered because it 
impacts both the length of the active layer and the amount 
of binding agent that may be immobilized in the active layer 
(i.e. binding capacity of the column). Preferably, the particle 
Size is Smaller than the length of the desired active layer. 
Applicants have found that a preferred particle diameter is 
less than about 10 times to about 20 times the length of the 
active layer because particles within this size range facilitate 
uniform packing of the layer by allowing Small packing 
defects to average out and produce a more uniform packing 
croSS-Section for the Support. In addition, the Support par 
ticles should be able to tolerate the flow rates and pressures 
needed in order to obtain the desired Sample contact time 
with the active layer. The properties that affect the pressure 
and flow rate that may be tolerated by the Support particles 
include the diameter of the particle, the particle's shape and 
the porosity of the particles. Suitable Support particles 
include porous or nonporous glass, Silica and other inorganic 
Supports (e.g., alumina or Zirconia), carbohydrate-based 
Supports (e.g.,beaded agarose), and polymeric Supports (e.g., 
polymethacryltate or polystyrene based resins); however, 
one generally skilled in the art of chromatography can Select 
other appropriate Support particles. 
The microcolumn may comprise a single inert layer or 
Several inert layers, depending upon the application. 
However, common features shared by all inert layers, irre 
spective of their number or position within the 
microcolumn, is that they typically should have no Substan 
tial interaction with the target analyte, and should preferably 
be mechanically stable under the flow rate and pressures 
employed during the Separation process. Preferable materi 
als for construction of the inert layer include diol-bonded 
Silica, diol-bonded glass beads, agarose beads, hydroxylated 
perfusion media, and glycol coated perfusion media. The 
various inert layerS may be constructed from the same 
Support particles or different Support particles. However, it is 
usually preferred for the Sake of convenience in loading the 












The layers in the microcolumn may comprise either an 
active layer alone, or an active layer and a single inert layer 
on top of the active layer (wherein the active layer is in 
communication with the Second end retaining means) Such 
that liquid first passes through the inert layer and then passes 
through the active layer. The utilization of a single inert layer 
in this manner is especially Suitable for applications where 
the liquid (containing the sample) is to be applied in only a 
Single direction to the active layer and the column. The inert 
layer in this application preferably occupies the entire length 
of the microcolumn between the beginning of the first end of 
the microcolumn to the beginning of the active layer So that 
the entire microcolumn is filled with Support particles. 
Applicants have found that having the entire microcolumn 
filled with Support particles increases both the Speed and 
efficiency of Separation. Additionally, the inert layer in this 
application also preferably acts to distribute the injected 
Sample evenly acroSS the diameter of the column before the 
Sample reaches the active layer. This allows for a more 
uniform application of the Sample to the relatively thin 
active layer. 
The layers in the microcolumn may also comprise an 
active layer Sandwiched between a top and a bottom inert 
layer. As utilized herein, the term “top inert layer” shall 
mean the layer that liquid first passes through prior to 
reaching the active layer and “bottom inert layer shall mean 
the layer where liquid passes after it exits the active layer. 
The microcolumn preferably comprises both a top and 
bottom inert layer for applications where liquid is to be 
applied in two directions to the active layer and the column. 
At any given time, the flow of liquid through the column is 
generally only in a single direction. However, it is Some 
times preferable to alternate the flow of liquid through the 
column in order to help wash out any impurities that may 
have built up at the top of the column during the application 
of liquid. The top inert layer in this application Serves the 
Same role as discussed above for the application employing 
a single inert layer e.g. more efficient Separation. However, 
applicants have found that it is preferable to include the 
bottom inert layer, even in applications where fluid flow is 
in only a single direction, because its inclusion increases the 
useful life of the active layer by preventing loSS of Support 
particles. 
The thickness of the inert layerS is not a critical feature 
and does not affect the time needed to Separate the free 
fraction of an analyte from the sample. In general, as Stated 
above, the top inert layer is preferably the length that 
remains between the beginning of the column and the 
beginning of the active layer. And, the bottom inert layer, if 
it is present, is generally from about 1 to about 5 times the 
length of the active layer. Typically, the top inert layer is 
thicker than the bottom inert layer. 
The choice of a particular type of housing for the micro 
column is also not a critical facet. The microcolumn 
housing, however, preferably employs components made of 
materials that are Substantially inert to biological fluids and 
in particular, Substantially inert to the analyte So as not to 
interfere with the Separation process. Accordingly, any mate 
rial that is Substantially inert may be employed to construct 
the microcolumn. Suitable materials include Stainless Steel, 
polypropylene, certain plastics and fused Silica. 
The dimensions of the microcolumn are also not a critical 
feature. Any size of microcolumn may be utilized to the 
extent that the total column length is preferably greater than 
the length of the active layer. The total column length and 
diameter also preferably allow the use of sufficiently fast 
flow rates and pressures to achieve the desired contact time 
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between the sample and the active layer. Preferably, the 
microcolumn has an internal diameter of about 50 microns 
to about 2 centimeters and a length of about 0.2 millimeters 
to about 2 centimeters. In a particularly preferred 
embodiment, the microcolumn has an internal diameter of 
about 0.5 to about 2.1 millimeters and a length of about 1 
millimeter to about 2 centimeters. 
Applicants have found that thin active layerS may pref 
erentially be obtained by loading the Support particles com 
prising the layer into the microcolumn via a plurality of 
injections, as described in detail below (e.g. see FIG.3). The 
normal method of loading a column, applying the Support 
particles in one application to the column with the amount 
of Support particles being in exceSS of that which is needed 
to fill the column, is Sufficient for Standard Size chromatog 
raphy columns because due to their size, reliable packing of 
the Support particles may be achieved. 
Applicants, however, have found that loading the Support 
particles in a Single injection, for columns with dimensions 
described herein, generally does not result in an active layer 
capable of consistently achieving Separation of an analyte 
from a Sample in the millisecond time Scale. 
Accordingly, the layers are preferably loaded into the 
column by a plurality of injections of Slurry comprising the 
Support particles. The Slurry may be injected into the column 
employing any apparatus generally known for injecting a 
Slurry into a column, for example, a closed-loop Sample 
application System with either a manual injection valve or an 
automatic injection System may be utilized. The slurry, in 
addition to Support particles, also preferably comprises a 
packing Solvent or buffer. The packing Solvent employed to 
load the slurry into the column is not a critical feature; 
however, the solvent preferably will not harm the binding 
agent present in the active layer. One skilled in the art of 
chromatography can readily Select both an appropriate appa 
ratus to inject the slurry and appropriate packing Solvents. 
Applicants have also found, as illustrated by FIG. 3, 
employing a larger number of injections and leSS Support per 
injection, achieves a more controlled delivery of Support 
particles because Statistical variations that occur during the 
delivery of Small amounts of Support particles to the column 
are averaged out. This is particularly true as layer thickneSS 
decreases. Uniform packing of Support particles in the 
layers, especially the active layer, is preferable because it 
provides more reproducible results for injected Samples by 
allowing parts of the Sample that are injected at different 
locations along the diameter of the column to achieve 
consistent Sample contact times with the active layer. 
Accordingly, the number of injections to introduce a layer 
into the column is generally from about 10 to about 100. 
More preferably, the number of injections to introduce a 
layer is from about 30 to about 40 when the layer length is 
from about 100 to about 500 microns, and is from about 60 
to about 80 injections when the layer length is from about 60 
to about 100 microns in length. 
The slurry density (milligrams of Support particles per 
milliliter of packing Solvent), or amount of Support particle 
applied to the column per injection, will vary greatly 
depending upon the desired thickness of the layer. 
Typically, however, the slurry density will be from about 
0.1 to about 20 milligrams of support particles per milliliter 
of packing Solvent and more preferably, will be from about 
1 to about 5 milligrams of Support particles per milliliter of 
packing Solvent. In general, the inert layer(s) and active 
layer are loaded at approximately the same Slurry density. 











appropriate slurry density needed to achieve a layer having 
a particular thickneSS when employing a Specific number of 
injections. 
The desired slurry density, once Selected, is preferably 
maintained throughout column injection in order to facilitate 
uniform layer packing. To maintain consistent Slurry density, 
the Slurry typically undergoes Shaking between injections to 
ensure that the Support particles are uniformly distributed in 
the slurry. It is also preferable to monitor the turbidity of the 
Slurry at a wavelength of approximately 800 nm to ensure 
the amount of Support particles per milliliter remains con 
Stant. Furthermore, typically the Slurry density is calculated 
at numerous points during injection by comparison to Slur 
ries of known density employing the same Support particles. 
Applicants have also found, in addition to loading the 
Support particles by a plurality of injections, that varying the 
flow rate and pressure during column loading also serves to 
provide a more uniform and thin active layer. In a particu 
larly preferred application, the pressure and flow rate are 
increased for a short period of time near the beginning and 
end of the loading of each layer (as illustrated in Table 1). 
This increased pressure and flow rate facilitates compression 
of the layer and distributes the Support particles within the 
layer evenly acroSS the diameter of the column. In a typical 
column loading procedure, for example, the flow rate of 
slurry injection into the column is between about 3 mL/min 
and about 5 mL/min, with the higher flow rate occurring 
generally at the beginning and end of the loading of each 
layer. 
Additionally, pressure during column loading is typically 
maintained between about 2000 and about 4000 psi, with a 
higher pressure preferably occurring at the beginning and 
end of the loading of each layer. The particular flow rates 
and preSSures utilized to load each layer of the column is not 
a critical feature and accordingly, may be varied Signifi 
cantly from the general examples provided hereindepending 
upon the particular application. 
Table 1 Sets forth a general procedure for loading a 1.0 cm 
immunoaffinity microcolumn comprising an active layer 
between a top and bottom inert layer. The procedure set forth 
in Table 1 is for illustrative purposes only and shall not be 
construed to limit the Scope of the present invention as 
described in greater detail herein. 
TABLE 1. 
General Procedure for Preparing a Microcolumn 
1 Assemble column fittings on the second end of the 
microcolumn (and retaining means) and attach the 
microcolumn to the packing apparatus; 
2 Make two particle support slurries in the packing 
solvent, one consisting of inert support particles, and 
the other containing the active support particles. For 
an immunoaffinity microcolumn, the packing solvent 
employed may be pH 7.0, 0.10 M potassium phosphate 
buffer and the slurry of the inert support particles 
typically may contain a diol-bonded material (e.g. 2 
mg/mL diol-bonded silica). The second slurry contains 
the immunoaffinity support particles at a concentration 
that is determined by utilizing equation 2 or any other 
generally known method (as set-forth in the examples 
below) and the desired thickness of the final active 
layer 
3 Begin flow of the packing solvent through the column. 
This is generally done at a rate of approximately 3 
mL/min for immunoaffinity microcolumns, but is not 
critical. Make approximately five injections (at 150 
uL per injection for a 1.0 cm long column) of the inert 
support slurry, followed by an increase in flow rate to 
approximately 5 mL/min for approximately 5 minutes 
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TABLE 1-continued 
General Procedure for Preparing a Microcolumn 
4 Return the flow rate to approximately 3 mL/min and make 
the required number of injections of the active layer 
(per equation 2 or any other generally known method). 
After making these injections, increase the flow rate 
to approximately 5 mL/min for approximately 5 minutes 
5 Return the flow rate to approximately 3 mL/min and make 
enough injections of the inert support slurry to fill 
the remainder of the column bed 
6. After the column bed has been filled, increase the 
column backpressure to the desired level, typically 
about 3000 to about 4000 psi. Allow the column to 
equilibrate at this pressure for approximately 10 
minutes. Gradually release the pressure. Remove the 
column from the packing apparatus and place a frit 
(retaining means) and end fitting onto the open end of 
the column. The column is now ready for use 
The microcolumn, in addition to its relatively thin active 
layer, is also generally able to tolerate flow rates and 
preSSures during Sample injection that are capable of achiev 
ing the desired Sample contact time with the active layer. The 
flow rate and preSSure depends not only on the Support 
particles employed in layer construction, but also on the 
column diameter and upper pressure limit that can be 
tolerated by the chromatographic System. In general, any 
flow rate and preSSure necessary to achieve the desired 
residence time and tolerated by the chromatographic System 
employed is within the Scope of the present invention. 
Typically, however, the microcolumns may be Subjected to 
flow rates of between about 0.01 to about 9.0 mL/min and 
pressures between about 10 to about 6000 psi. More 
preferably, the pressure is between about 100 to about 1500 
psi. 
II. Determination of the Free Analyte Fraction 
Encompassed in the method of the invention is a means to 
determine the concentration of the free analyte fraction in a 
ample comprising a free fraction and a bound fraction. The 
method entails generating a calibration curve comprising 
data obtained by analyzing a Series of Standards containing 
a known concentration of the same analyte present in the 
Sample. The concentration of the free analyte present in the 
Sample, as described in detail below, is then determined by 
comparison to the calibration curve. 
Applicants have found that accurately determining the 
concentration of free analyte in a Sample preferably involves 
the rapid and Selective extraction of this fraction from the 
Sample before significant release from its bound fraction. 
Additionally, applicants have found that this release gener 
ally occurs within a few Seconds, particularly when the 
analyte binds a Serum protein or other binding compound, 
Such as HSA or alpha 1-acid glycoprotein. The affinity 
microcolumns described in detail above, therefore, are par 
ticularly Suited for the method of the invention because they 
are capable of Selectively extracting the free fraction within 
the millisecond time domain. The bound fraction, on the 
other hand, does not bind to the affinity column and is 
therefore present in the liquid fraction that passes through 
the column. 
Accordingly, the method of the invention encompasses 
applying a sample to the affinity column (described in detail 
above) under conditions sufficient to bind the free analyte 
fraction without Significant interference from its bound 
fraction, which passes through the column without adsorb 











entails applying a Series of Standards to the same affinity 
column. "Standard” as utilized herein, shall mean a mixture 
that contains a known concentration of the analyte. The 
Standard will preferably comprise the same analyte as is 
being detected in the Sample and depending upon the 
embodiment of the invention, may also comprise a binding 
compound. “Series of Standards” as utilized herein, shall 
mean applying from about two to about five Standards with 
different analyte concentrations to the column. In another 
embodiment of the invention, the Series of Standards may be 
determined without applying the Standards to the column for 
each application of the method, Such as when the calibration 
curve has been determined previously (from analysis of the 
same standard in an earlier test) or when the Standard comes 
as a part of a kit. The series of standards will preferably 
contain concentrations of free analyte that are Substantially 
comparable to the concentration of free analyte expected to 
be present in the Sample. 
In accordance with the method of the invention, the 
concentration of free analyte present in each Standard is 
determined. This concentration may be determined based 
upon mass or Volume measurements in which a known 
concentration of pure analyte is weighed and placed into a 
known volume of Solution. Equally, a known volume of 
solution may be diluted or combined with another solution 
to prepare the final Standard Solution. In addition to these 
methods, the concentration may be determined by any 
means generally known in the art. 
Additionally, the Sample and Standard, irrespective of the 
embodiment of the invention, are preferably injected onto 
the column under conditions that optimize a rapid and 
Selective binding of the free analyte to the column. A number 
of conditions may impact the degree of free analyte binding 
to the column. These conditions are preferably optimized to 
achieve a high rate of binding and generally include: 1) an 
active binding agent in the column that is 35 capable of 
binding the free analyte, 2) Solution conditions (as set forth 
in more detail below) preferably favorable for binding to 
occur, 3) the binding capacity of the column is preferably 
equal to or greater than the concentration of free analyte 
injected into the column (as discussed above), and 4) the 
residence time is typically optimized Such that the time is 
preferably long enough that a Significant concentration of 
the free analyte binds to the column and yet, short enough 
in duration to prevent significant dissociation from the 
bound fraction. The Sample and Standards may be applied to 
the column by any means generally known in the art, Such 
as through the use of an injection valve or autoninjector 
System. 
In addition to the parameters Set forth above impacting 
binding capacity, a number of operating conditions 
employed during Sample and Standard injection onto the 
column are also preferably optimized. One Such operating 
parameter is Selection of the loading and elution buffers. The 
buffers selected preferably mimic the pH and solvent con 
ditions of the Sample to ensure that the equilibrium between 
the free and bound fractions is not disrupted. For example, 
when a biological Sample is being analyzed, any physiologi 
cal buffer, Such as phosphate buffer, may be employed. And, 
the buffer typically will have a pH of approximately 7.2 to 
about 7.4 (pH of blood, serum or plasma). The temperature 
during injection of Standard/sample onto the column is also 
important. Again, the temperature will preferably mimic the 
natural temperature of the Sample to avoid disrupting the 
binding properties of proteins in the Sample prior to their 
application to the affinity column. Additionally, applicants 
have found that flow rate during Sample injection can 
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dramatically impact both extraction efficiency and dissocia 
tion of analyte from the bound fraction. Typically higher 
flow rates result in leSS dissociation, while slower flow rates 
increase extraction efficiency. Therefore, an intermediate 
flow rate is preferably employed during column injection 
and one generally skilled in the art of chromatography can 
readily determine this rate, which will vary depending upon 
the particular application. Typically, however, the flow rate 
is from about 0.1 to about 10.0 ml/min, and even more 
preferably, the flow rate is from about 0.5 to about 1.5 
ml/min. 
Accordingly, in one embodiment of the invention the 
concentration of free analyte present in the Sample is deter 
mined by analyzing data from a Series of Standards com 
prising known concentrations of the same free analyte 
present in the Sample without the presence of any binding 
compounds. In this embodiment, therefore, the concentra 
tion of the free fraction is determined by directly analyzing 
data from the free fraction of the series of standards (“Direct 
Method”). The sample, as detailed above, is applied to the 
column employing the same operating parameters as with 
injection of Standard onto the column. The column Separates 
the Sample and Series of Standards into a free fraction and a 
bound fraction in the millisecond time domain. AS detailed 
above, the free fraction of both the standard and sample is 
adsorbed to the column, while the bound fraction passes 
through the column. 
The free analyte fraction of both the standard and sample 
isolated by the column is typically then detected as a signal 
by any means generally known in the art of analytical 
chemistry. “Signal” as utilized herein, shall mean the chemi 
cal or physical response that allows the analyte to be 
detected (in either the standard or Sample). The signal can 
either be generated by the analyte itself (e.g. see detection of 
warfarin in the Example below) or generated by another 
compound that is linked to the analyte (e.g. the use of a 
labeled analog of an analyte to allow the unlabeled analyte 
to be detected). In addition, the signal is specific to the 
particular detection method employed. The choice of a 
particular detection method is not critical. However, the 
detection method employed is preferably the same for both 
the Standard and Sample in order to generate a reliable 
calibration curve. Detection may be performed by either an 
on-line or off-line method. An "on-line” method, as utilized 
herein, shall mean a method in which there is a direct 
coupling between isolation of the free fraction (via affinity 
chromatography) and its detection Such that the isolated 
fraction is automatically transferred to the detection mecha 
nism through an interface that connects the two Systems. An 
“off-line” method, on the other-hand, as utilized herein, shall 
mean a method in which the isolated fraction is collected and 
then manually transferred to the detection mechanism. Suit 
able detection methods include immunoassay, mass 
Spectrometry, gas chromatography, and detection based 
upon ultraViolet absorbance, fluorescence detectors, and 
electrochemical detectors. Preferably, however, the detec 
tion technique utilized will comprise an on-line method with 
direct detection in order to facilitate efficiency of Such 
detection. 
The calibration curve can then be generated after the 
isolation and Subsequent detection of Signal, as detailed 
above, of the Standard with known concentrations of free 
analyte. The calibration curve comprises a graph depicting 
the concentration of free analyte present in each Standard 
Versus the Signal detected for each concentration. 
Additionally, the plot can be generated either manually, 











computer program generally known in the art for linear or 
non-linear regression. 
The concentration of the free fraction present in the 
Sample can then be readily determined utilizing the calibra 
tion curve delineated above by Simply comparing the Signal 
detected from the free analyte fraction Separated from the 
Sample with the array of Signals depicted on the calibration 
curve. This direct comparison is possible because the curve 
depicts the Signal for known concentrations of the free 
fraction (generated from the Series of Standards). Therefore, 
the concentration of the free fraction of the Sample may be 
determined by comparing its signal to signal depicted in the 
calibration curve for the standards with known free analyte 
concentrations. 
In yet another embodiment, the concentration of the free 
analyte fraction of the Sample is determined by analyzing 
data from a Series of Standards comprising known concen 
trations of the same free analyte present in the Sample and 
a binding compound. In this embodiment, in contrast to the 
Direct Method detailed above, the concentration of the free 
fraction of the Sample is determined by analyzing data from 
the bound fraction and a total fraction (described below) 
from the series of standards (“Indirect Method”). In this 
embodiment, Similar to the embodiment delineated above, 
the Sample and Series of Standards are applied to the affinity 
column employing the same operating parameters. The 
column Separates the Sample and Series of Standards into a 
free fraction and a bound fraction in the millisecond time 
domain. Additionally, the free fraction of both the standard 
and sample is adsorbed to the column while the bound 
fraction passes through the column. In the Indirect Method, 
in contrast to the Direct method, the bound fraction of both 
the sample and Series of Standards is retained for further 
analysis in the next Step of the method. 
However, also in contrast to the Direct Method, the 
Indirect method employs the use of an additional inert 
control column. In this embodiment, the same Sample and 
Series of Standards applied to the affinity column described 
above are applied to an inert control column. The inert 
control column comprises a column constructed in all details 
like the affinity column discussed above except that the 
Support particles in its active layer are not derivatized with 
a binding agent. For example, the inert control column and 
affinity column employed in this embodiment are the same 
size, are constructed from the same materials, and are 
operated under the same parameters (i.e. pressure and flow 
rate). However, because the inert control column is not 
derivatized with binding agent, the free analyte fraction is 
not separated from either the Sample or Series of Standards. 
Instead, a total analyte fraction comprising the bound frac 
tion and free fraction pass through the column. The total 
fraction is retained from both the Sample and Series of 
Standards for further analysis in the next Step of the method. 
The signal of the bound fraction of both the sample and 
Series of Standards is then detected by any means generally 
known in the art of analytical chemistry, as described in 
detail above for the Direct Method. In addition, the signal of 
the total fraction of both the Sample and Series of Standards 
is also detected in accordance with the procedures described 
above for the Direct Method. 
In contrast to the Direct Method, the Indirect Method 
entails generating two calibration curves. The first calibra 
tion curve comprises a graph depicting the concentration of 
analyte present in the bound fraction for each Standard 
Versus the Signal detected for each concentration. The Sec 
ond calibration curve comprises a graph depicting the con 
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centration of analyte present in the total fraction for each 
Standard versus the Signal detected for each concentration. 
AS described above, the calibration curves can be generated 
either manually, with a spreadsheet (e.g. Lotus or Excel) or 
by employing any computer program generally known in the 
art for linear or non-linear regression. 
In accordance with the method of the invention, the 
concentration of the free analyte fraction present in the 
Sample can then be determined utilizing the two calibration 
curves described above. The concentration of the bound 
analyte fraction present in the Sample can readily be deter 
mined by comparing the Signal detected for the bound 
fraction of the Sample with the calibration curve depicting 
the signal detected from the bound fraction of the series of 
Standards with known analyte concentrations. The concen 
tration of the total fraction present in the Sample can also be 
readily determined by comparing the Signal detected for the 
total fraction present in the sample with the calibration curve 
depicting the Signal detected from the total fraction of the 
Series of Standards with known analyte concentrations. 
Finally, per this method, the concentration of free analyte 
present in the Sample can be determined by Simply Subtract 
ing the concentration of the bound fraction present in the 
Sample from the concentration of the total fraction present in 
the Sample. 
The methods of the present invention may be employed to 
determine the free analyte fraction of any Sample comprising 
a bound and free fraction, to the extent that the free fraction 
is capable of being Separated from the Sample, as described 
herein. A typical application for the method, however, is the 
clinical analysis of the free fraction of a hormone, drug and 
other endogenous or exogenous agents present in biological 
Samples. The method may also be employed for the phar 
maceutical analysis of free drug levels or drug metabolite 
levels in biological Samples. Equally, the method may be 
employed in toxicology Studies to quantify the free fraction 
of organic compounds and/or inorganic compounds present 
in a Sample. In a research Setting, the method may be utilized 
to Study the mechanism of protein binding processes. 
The detailed description set-forth above is provided to aid 
those skilled in the art in practicing the present invention. 
Even So, this detailed description should not be construed to 
unduly limit the present invention as modifications and 
variation in the embodiments discussed herein can be made 
by those of ordinary skill in the art without departing from 
the Spirit or Scope of the present inventive discovery. 
All publications, patents, patent applications and other 
references cited in this application are herein incorporated 
by reference in their entirety as if each individual 
publication, patent, patent application or other reference 
were specifically and individually indicated to be incorpo 
rated by reference. 
Without further elaboration, it is believed that one skilled 
in the art can, using the preceding description, utilize the 
present invention to its fullest extent. The following pre 
ferred Specific embodiments are, therefore, to be construed 
as merely illustrative, and not limitative of the remainder of 
the disclosure in any way whatsoever. 
EXAMPLES 
The examples illustrate the ability of the method of the 
present invention to detect the free fraction of warfarin from 
a Sample comprising warfarin and human Serum albumin 
(“HSA'). Warfarin is one example of a drug which has 
Significant binding in blood, and is a common anticoagulant 











attacks and Strokes. It exists in two enantiomeric forms, 
R-(+)- and S-(-)-warfarin, which are given as a racemic 
mixture. Both forms have pharmacological activity, but 
S-warfarin is Several times more potent than the 
R-enantiomer. In the circulation, R- and S-warfarin exist 
mainly in their bound forms, with most of this binding 
occurring with the protein HSA. Because of warfarin's 
pharmaceutical significance, binding affinity for HSA, and 
Stereochemistry, it is an excellent model to illustrate the 
broad applicability of the method of the current invention. 
Materials and Methods 
Reagents. The R- and S-warfarin were donated by Dupont 
Pharmaceuticals (Wilmington, Del.). The polyclonal anti 
warfarin antibodies were from Accurate Chemical 
(Westbury, N.Y.). The HPLC-grade Nucleosil Si-500 and 
Si-1000 silica (7 um particle size, 500 A and 1000 A pore 
size) was obtained from Alltech (Deerfield, Ill.). The 
7-amino-4-coumarin-3-acetyl hydrazide (AMCA 
hydrazide) and reagents for the bicinchoninic acid (BCA) 
protein assay (Smith, P. K.; Krohn, R.I.; Hermanson, G. T.; 
Mallia, A. K., Gartner, F. H.; Provenzano, M. D.; Fujimoto, 
E. K., Goeke, N. M., Olson, B. J., Klenk, D. C. Anal. 
Biochem. 1985, 150, 76.) were from Pierce (Rockford, Ill.). 
HSA (Cohn fraction V, 99% pure, fatty acid free) and rabbit 
immunoglobulin G (IgG) were purchased from Sigma (St. 
Louis, Mo.). All other chemicals were reagent-grade or 
better. All aqueous Solutions were prepared using deionized 
water from a Nanopure water System (Barnstead, Dubuque, 
Iowa). 
Apparatus. Samples for the BCA protein assay were 
analyzed using a Shimadzu UV160U absorbance spectro 
photometer (Kyoto, Japan). Immunoaffinity columns were 
packed using a modified N60 injection valve from Valco 
(Houston, Tex.) and a CM3000 HPLC pump from LDC 
Analytical (Riviera Beach, Fla.). The final chromatographic 
System used in the analysis of free and bound warfarin 
consisted of one anti-warfarin immunoaffinity microcolumn 
(prepared as described later) in Series with two 5 cmx2.1 
mm ID Pinkerton GFF II internal surface reversed-phase 
(ISRP) columns from Regis Technologies (Morton Grove, 
Ill.). Detection in the chromatographic System was per 
formed by a Shimadzu RF-535 fluorescence monitor. 
Samples were injected by an AS3000 autosampler from 
Thermoseparations (Schaumberg, Ill.). The application and 
elution buffers for the immunoaffinity column were deliv 
ered using PU-980 HPLC pumps from Jasco (St. Louis, 
Mo.). A LABPro automated six-port valve from Rheodyne 
(Cotati, Calif.) was used to switch between these buffers. An 
organic modifier for displacement of the HSA-bound war 
farin was introduced to the effluent of the immunoaffinity 
column through the use of a post-column mixing tee and a 
CM3200 pump from LDC Analytical. The chromatograms 
were collected on a 300 MHZ Pentium computer from TCE 
(Hoffman Estates, Ill.) with Winner-on-Windows software 
from ThermoSeparations. The temperature of the System was 
controlled using a VWRbrand 13L immersion circulating 
water bath from VWR Scientific (West Chester, Pa.). 
Preparation of Immunoextraction Column. Antibodies 
were purified using AMCA-hydrazide as an affinity ligand. 
AMCA is a coumarin derivative that is similar in structure 
to warfarin. It was used here to isolate anti-warfarin anti 
bodies from their corresponding antiserum. The AMCA 
hydrazide was coupled to Nucleosil Si-1000 silica in a 
manner Similar to that reported for the Synthesis of 
dihydrazide-activated silica (Ruhn, P. F.; Garver, S.; Hage, 
D. S. J. Chromatogr. A 1994, 669, 9.). The anti-warfarin 
antibodies were isolated with this Support by incubating one 
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milliliter of anti-warfarin antiserum with 300 mg of the 
AMCA silica for two hours at room temperature. After 15 
incubation, the Samples were centrifuged and the Superna 
tant was removed. The Support was then washed with pH 
2.5, 0.10M potassium phosphate buffer for 10 min, followed 
by a Second centrifugation Step. This Second Supernatant 
(containing purified anti-warfarin antibodies) was then 
collected, adjusted to pH 7.0 with a small concentration of 
1.0 M sodium hydroxide, and stored at 4 C. until further 
Sc. 
Diol-bonded Nucleosil Si-500 silica was prepared as 
described previously (Ruhn, P. F.; Garver, S.; Hage, D. S. 
J. Chromatogr. A 1994, 669, 9.). The diol coverage of this 
Support was 127-4 (1 SD) umol/g of Silica, as determined in 
replicate by an iodometric capillary electrophoresis assay. 
The purified anti-warfarin antibodies were immobilized to 
this diol-bonded silica by the Schiff base method (Larsson, 
P-O. Methods Enzymol. 1984, 104, 2121). The protein 
content of the resulting immunoaffinity Support was deter 
mined by a BCA assay to be 2.05+0.05 mg antibodies/g 
Silica (or 14 nmol/g), using rabbit IgG as the standard and 
diol-bonded silica as the blank. 
The anti-warfarin immunoaffinity Support was used to 
pack a Sandwich microcolumn, as described herein. This 
column had an inner diameter of 2.1 mm and a total length 
of 1.0 cm, with a 1.1 mm portion containing the immunoaf 
finity Support and the remainder containing an inert layer of 
diol-bonded silica. The immunoaffinity layer was placed 
within this column by making thirty-two 250 till injections 
of a 0.3 mg/mL slurry of the anti-warfarin support in pH 7.0, 
0.10 Mphosphate buffer. The remainder of the column was 
filled in a similar manner with diol-bonded Nucleosil 500. 
Chromatographic Studies. The extraction Studies were 
performed by making 20 uL injections of 0.8-5x107 M 
warfarin at flow rates ranging from 0.5 to 3.0 mL/min. Five 
replicate injections were made at each flow rate using 
microcolumns that contained the immunoaffinity Support or 
only diol-bonded Silica. The non-retained peaks observed 
with the immunoaffinity column were compared to those 
Seen on the diol column to determine the relative concen 
tration of warfarin that had been removed by the immobi 
lized antibodies. The application buffer in these studies was 
pH 7.0, 0.10 M potassium phosphate and the elution buffer 
was pH 2.5, 0.10 M potassium phosphate. Between 
injections, the immunoaffinity column was washed for 5 min 
with the elution buffer at 1.0 mL/min and was allowed to 
regenerate for 10 min in the application buffer at 1.0 
mL/min. 
The separation of HSA and HSA-bound warfarin was 
studied by injecting 20 L of warfarin/HSA mixtures onto a 
diol microcolumn that was in series with two ISRP columns. 
The samples in this study contained 0-3.5x10 M war 
farin and 3 mg/mL (4.5x10 M) HSA in pH 7.0, 0.10 M 
phosphate buffer. These Samples were injected at 1.0 
mL/min in the presence of the pH 7.0 application buffer. A 
Separate Solvent Stream was introduced directly after the 
microcolumn using a three-way mixing tee. In the final 
optimized System, this Second Solvent Stream contained 
7.5% 1-propanol in pH 7.0, 0.10 M phosphate buffer and 
was added at a flow rate of 0.2 mL/min to induce dissocia 
tion of HSA-bound warfarin. The same chromatographic 
System was used to determine the concentration of free 
warfarin in warfarin/HSA mixtures by replacing the diol 
column with the immunoaffinity microcolumn. A Series of 
twenty replicate injections were made in this experiment 
using Samples that contained well-defined concentrations of 











the warfarin in these samples were then compared to the 
areas obtained for warfarin/HSA standards with the diol 
column. 
Computer Simulations. The simulations of warfarin 
extraction and dissociation were performed on an IBM 
compatible computer using programs written in Turbo C++ 
(Borland International, Scotts Valley, Calif.). This was 
accomplished by using a grid propagation algorithm that has 
previously been used to examine the adsorption of analytes 
to immobilized antibodies and Similar ligands in affinity 
columns. This algorithm was modified to include the revers 
ible binding of an analyte to an agent in the mobile phase. 
In this method, the column was divided into a large number 
of Slices of equal width. As an analyte moved through this 
column, its binding to the immobilized ligand and Soluble 
agent in each slice was described by using mass balance and 
the differential equations for the rates of these reactions. 
This System of equations was Solved for that particular Slice 
and interval of time by using a fourth-order Runga-Kutta 
method (Margenau, H.; Mosely, G. M. The Mathematics of 
Physics and Chemistry; Van Nostrand; Princeton, 1956.). 
Flow through the column was simulated after each iteration 
by taking the compounds that remained in the mobile phase 
and moving these onto the next Slice. The process of 
distributing and moving the analytes was repeated until all 
of the analyte had either bound to the immobilized ligand or 
had left the column. The relative concentration of analyte 
that had adsorbed to the column was then calculated, thus 
providing the retained fraction. Convergence of these results 
was tested by performing a Series of related Simulations in 
which the column was divided into an increasing number of 
Slices but with a decreasing concentration of time being used 
per iteration in each Slice. This gave a maximum estimated 
error of less than 0.2% in the calculated concentration of 
retained analyte. 
EXAMPLE 1. 
Initial Selection of Conditions for Free Drug 
Extractions 
Previous reports have measured the equilibrium and rate 
constants for the binding and dissociation of R- and 
S-warfarin with HSA under a variety of conditions (Loun, 
B.; Hage, D. S. Anal. Chem. 1994, 66, 3814 and Loun, B.; 
Hage, D. S. Anal. Chem. 1996, 68, 1218.). Based on this 
information, it was possible to estimate the time needed to 
remove the free fraction of warfarin from a warfarin/HSA 
mixture without having this fraction contain a significant 
concentration of warfarin that had been released from its 
protein-bound form. Some plots that were used to study the 
extent of this dissociation process are shown in FIG. 4 These 
particular results were calculated for S-warfarin at 25 C. 
under conditions similar to those used in this study. 
This type of plot was also generated for R-warfarin, which 
has a slightly faster rate of dissociation from HSA under the 
given experimental conditions. 
The model used in FIG. 4 assumes 1) that there is an 
instantaneous removal of all free warfarin from the initial 
Sample, 2) that any warfarin which is later released from its 
complex with HSA will bind immediately to the extraction 
column, and 3) that the concentration of extracted warfarin 
is much Smaller than the binding capacity of the column. 
Based on this model, it was found that roughly 75% of the 
S-warfarin that was originally bound to HSA would be 
released from this protein and adsorbed to the extraction 
column within 10s. This indicated that ordinary immunoaf 
finity extractions, which often take Several minutes to 
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perform, (Hage, D. S. J. Chromatogr: B 1998, 715, 3.) would 
be much too long for Separating the free and bound fractions 
of S-warfarin. An expanded view of this dissociation 
process, illustrated in FIG. 4 (b), indicated that extraction 
times of only a few hundred milliseconds would be required 
to isolate the free fraction of S-warfarin while avoiding any 
appreciable contamination by warfarin that had been later 
released from HSA. The same conclusion was reached in 
calculations that were performed for R-warfarin. 
Although it was useful in FIG. 4 to assume that there was 
an exceSS of binding sites in the column and that there was 
immediate removal of any non-complexed warfarin from 
Solution, this does represent a worst-case Scenario and 
probably resulted in estimates for the usable extraction times 
which were smaller than those that might be possible in 
practice. For instance, either the presence of a finite number 
of binding Sites in the column or a finite rate of adsorption 
for the non-complexed warfarin would reduce any pertur 
bation of the HSA-bound fraction of warfarin as this passes 
through the immunoaffinity column. The same thing would 
happen if the warfarin in Solution were allowed to reasSo 
ciate with HSA instead of being removed by the column. The 
effects of eliminating these assumptions will be considered 
through the use of computer Simulations. However, the 
model used in FIG. 4 was still found to be a good starting 
point for estimating the conditions needed in an immunoaf 
finity column for isolating a drugs free fraction. 
Design of Immunoaffinity Column. Based on FIG. 4, an 
extraction time of less than 200 ms was set as the initial goal 
for the removal of free warfarin from warfarin/HSA mix 
tures at room temperature. Under these conditions, an error 
of less than 20-40% in the measured free fractions of R- and 
S-warfarin was expected due to the dissociation of their 
protein-bound fractions. In order to work within this time 
frame it was necessary to prepare a column that was 35 
capable of operating in the millisecond time domain. This 
was accomplished by using a Sandwich microcolumn that 
was prepared as described herein. This consisted of a 2.1 
mm ID x 1.0 cm tube that was packed with a 1.1 mm thick 
layer of a Support that contained immobilized anti-warfarin 
antibodies. The remainder of the column was filled with 
diol-bonded Silica. The purpose of the immunoaffinity Sup 
port was to extract warfarin from Samples, while the diol 
bonded Silica was used to hold the immunoaffinity Support 
in place and to provide uniform Sample application to this 
layer. 
In this type of column the actual time over which free 
drug extraction and Sample perturbation takes place is 
represented by the time during which any given part of the 
Sample passes through the immunaffinity layer. For instance, 
an effective extraction time of 200 ms or less would be 
obtained by using a flow rate of at least 0.9 mL/min on a 2.1 
mm ID column that contains a 1.1 mm layer of an immu 
noaffinity support. This is well within the range of usable 
conditions for these columns, which have been operated at 
flow rates as high as 9-10 mL/min. 
The binding capacity of the immunoaffinity columns also 
had to be considered to ensure that overloading did not occur 
when warfarin Samples were injected onto these columns. 
The concentration of warfarin binding sites in one anti 
warfarin microcolumn was estimated to be 50 pmol. 
Although this is a relatively Small concentration of ligand, it 
is still three-to-five times larger than the concentration of 
free warfarin that was applied in any Sample, thus indicating 
that these columns did have a Sufficient binding capacity for 
this present Study. This was confirmed experimentally by 











could bind to the microcolumn as the concentration of 
injected warfarin was varied. 
One question that remained was whether this type of 
microcolumn could be used to extract warfarin on the 
millisecond time Scale. This was tested by injecting Samples 
that contained only R- or S-warfarin at various flow rates. 
The results obtained on the immunoaffinity column were 
then compared to those observed for the same Samples and 
flow rates on an inert control column. FIG. 5 shows an 
example of such a study. It was found that in 120 ms there 
was 95% extraction of a 5x107M warfarin sample (i.e., a 
concentration corresponding to the free warfarin content 
expected for the warfarin/HSA mixtures examined later in 
this report). At even lower concentrations, Such as the 
8x10 M warfarin sample shown in FIG. 5, essentially 
complete extraction was possible in 60 ms. Thus, it was 
concluded that immunoaffinity microcolumns could be used 
to extract warfarin on the same time Scale that was needed 
for Separating warfarin's free and protein-bound fractions. 
EXAMPLE 2 
Separation of Free and Bound Warfarin Fractions. 
The next Section of this Study began to examine the use of 
an immunoaffinity microcolumn to measure the free drug 
fractions of mixtures that contained known concentrations of 
HSA and R- or S-warfarin. This was to be done by moni 
toring the fluorescence of any warfarin that passed non 
retained through the immunoaffinity column. One difficulty 
with this approach is that warfarin has a significant change 
in its degree of fluorescence when it is in Solution verSuS 
bound to HSA. This, plus the inherent fluorescence of HSA, 
created a problem in detection because the non-retained 
samples were expected to contain a mixture of HSA, HSA 
bound warfarin, and warfarin that had dissociated from 
HSA 
The approach used to overcome this problem was to pass 
the non-retained Sample peaks through a Series of ISRP 
(internal Surface reversed-phase) columns. This was done by 
using the system illustrated in FIG. 6. Although all of the 
bound warfarin would eventually be released from HSA in 
Such a System, a dissociating agent (1-propanol) was added 
to the microcolumn effluent to increase the rate of this 
proceSS. 
The 1-propanol also acted as an organic modifier to aid in 
the elution of components on the ISRP columns. 
A typical chromatogram for this System is shown in FIG. 
7. As demonstrated in earlier studies, proteins like HSA are 
too large to fit in the pores of an ISRP column and will elute 
in its excluded volume. However, Smaller molecules like 
warfarin can enter these pores and interact with the hydro 
phobic phase that is located there. This will cause these 
molecules to be retained and to elute after proteins from 
these columns. In the case of this study, the Second peak was 
much broader than the first since it was produced by 
warfarin that entered the pores at different points along the 
column as it began to undergo dissociation from HSA. 
ISRP columns have been used alone for the analysis of 
free and bound warfarin in the presence of bovine Serum 
albumin. In these earlier Studies, the free warfarin was 
retained at the beginning of the ISRP column, while the 
bound fraction underwent dissociation from albumin and 
was retained further downstream. It was shown that this 
resulted in three overlapping peakS: the first representing the 
non-retained protein, the Second corresponding to warfarin 
which dissociated from this protein, and the third (and 
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slowest eluting peak) representing warfarin's initial free 
fraction. It is important to note in this present Study that the 
free warfarin peak was not observed on the ISRP column 
when the Samples had previously passed through the immu 
noaffinity column. This occurred because the free fraction 
had now been removed from these samples. This allowed a 
much cleaner Separation to be obtained between the bound 
and free fractions of this drug and its binding proteins than 
was reported when using only ISRP supports. 
Various factors were adjusted to obtain the Separation 
shown in FIG. 7. The rate of warfarin dissociation from HSA 
was increased in the ISRP column by adding 1-propanol to 
the effluent of the immunoaffinity column. This resulted in 
a sharper peak for the bound warfarin fraction Since it was 
now released over a shorter distance within the ISRP col 
U. 
A 7.5% solution of 1-propanol was found to be optimum 
for this purpose Since it allowed complete dissociation of 
warfarin from HSA in a reasonable time while still providing 
a large enough difference in retention for their separation. A 
longer length for the ISRP support was also employed 
(going from one 5 cm long column to two 5 cm columns) to 
increase the efficiency of this System and its ability to 
resolve the HSA and bound warfarin peaks. The result was 
a separation in which baseline resolution was obtained 
within 5 min of Sample injection. 
One Small problem in using multiple ISRP columns was 
that this increased the back pressure of the overall chro 
matographic System. This placed a limit on the maximum 
flow rate and minimum Sample residence time that could be 
used with the immunoaffinity microcolumn. As a compro 
mise between extraction time, Sample throughput and these 
preSSure limitations, an injection flow rate of 1.0 mL/min 
was chosen for the final System. This gave a residence time 
of 180 ms for samples in the immunoaffinity column. As 
noted earlier, this concentration of time not only was Suff 
cient to allow the quantitative extraction of warfarin, but it 
also fell within the range of 200 ms or less that was initially 
Selected for use in Separating warfarin's free and bound 
fractions. 
EXAMPLE 3 
Analysis of Free Warfarin Fractions 
The fourth phase of this study used the immunoaffinity 
and ISRP system to measure the concentration of free 
warfarin in known mixtures of warfarin and HSA. To 
quantitate the free warfarin in these samples, Standard curves 
were first prepared in which various concentrations of R- or 
S-warfarin were mixed with HSA. These mixtures were then 
injected onto the system shown in FIG. 6, with diol-bonded 
Silica being used in place of the immunoaffinity Support in 
the extraction column. The area of the warfarin that eluted 
from the ISRP columns (now corresponding to both the 
bound and free warfarin fractions) was measured and plotted 
as a function of the total warfarin concentration in the 
Sample. Both R- and S-warfarin gave linear responses in 
these plots with correlation coefficients of 0.9991-0.9993 
for ten Samples that contained warfarin concentrations of 
0-1.7x10 M. The lower limit of detection of this method 
for these enantiomers was about 0.5-1x10 M (S/N=2). 
This detection limit was 50 to 100-fold Smaller than the free 
warfarin concentrations which were measured in this study. 
The warfarin and HSA mixtures that were being used as 
test Samples were now injected onto the same System in the 











bonded silica or 2) the immunoaffinity column that had 
previously been developed for the millisecond-Scale extrac 
tion of warfarin. The peak area obtained with the diol 
column allowed the total concentration of warfarin in the 
Sample to be determined. The area measured after extraction 
by the immunoaffinity column allowed the concentration of 
bound warfarin to be estimated. By combining these two 
values it was then possible to calculate the concentration of 
free warfarin in the Sample. 
This approach was tested by injecting a Set of Samples that 
contained 0.95-1.10x10 MR- or S-warfarin and 4.5x10 
M HSA. Both the R- and S-warfarin samples were injected 
twenty times onto the diol column and immunoaffinity 
column. This gave relative standard deviations of +4-6% for 
their measured peak areas on the ISRP system. The free 
fractions that were obtained for these Samples are shown in 
Table 2, below. For R-warfarin, the free fraction was deter 
mined to be 11.8+0.6% at 25 C. (or a bound fraction of 
88.2%), while for S-warfarin the free fraction was 5.9+0.2% 
(or 94.1% bound). 
TABLE 2 
Measured and predicted free fractions for R- and S-warfarin 
in Samples containing known mixtures of warfarin and HSA" 
Measured Free Predicted free 
Compound Fraction Fraction 
R-Warfarin 11.8 (+0.6) 7% 10 (+2) 7% 
S-Warfarin 5.9 (+0.2) 7% 7 (+1) 7% 
All values shown in parentheses represent a range of t1 SD. 
The predicted free fractions were determined by using the known compo 
sitions of the samples and equilibrium constants which have previously 
been measured for the binding of warfarin enantiomers to HSA at 25 C. 
The equilibrium constants that were used for R- and S-warfarin were 2.6 (+0.1) x 10 M and 3.4 (+0.1) x 10 M', respectively. 
The accuracy of these free fractions was evaluated by 
comparing them with the predicted results for these samples. 
This was accomplished by using the known composition of 
these Samples and equilibrium constants that have previ 
ously been determined for the binding of R- and S-warfarin 
to HSA under conditions similar to those used in this study 
(Loun, B.; Hage, D. S. Anal. Chem. 1994, 66,3814). It was 
assumed in these calculations that essentially all of the HSA 
was active; this was confirmed experimentally through the 
use of fluorescence and a Solution-phase titration of the HSA 
with increasing concentrations of warfarin. For R-warfarin, 
it was predicted that approximately 10+2% of this drug 
would be in the free form at equilibrium for the given sample 
composition, while for S-warfarin a predicted free fraction 
of 7+1 was obtained. Both predicted results were within one 
Standard deviation of the experimental free fractions, thus 
indicating that there was good agreement between these 
values. 
An inherent assumption made throughout this project was 
that the anti-warfarin antibodies in the immunoaffinity col 
umn would be able to distinguish between the free warfarin 
in Solution and its HSA-bound fraction. For this to be true, 
these antibodies would have to interact with regions in the 
Structure of warfarin that were not exposed when this drug 
was complexed with HSA. The agreement between the 
actual and predicted results in Table 2 indicates that this was 
indeed the case. This specificity for the free versus bound 
fractions was not Surprising in the case of R-warfarin, which 
is believed to interact deep within its binding site on HSA. 
But a similar specificity was noted for S-warfarin, which is 
thought to interact more with HSA's outer Surface. This 
result indicates that it should be possible to use immunoaf 
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finity chromatography to isolate the free fractions of drugs 
that have a variety of different orientations in their drug 
protein complexes. However, as a precaution, it is still 
recommended that antibody Specificity always be consid 
ered for any new compounds that are to be examined by this 
analytical technique. 
EXAMPLE 4 
Simulation of Warfarin Extraction and Dissociation 
After the free fractions of R- and S-warfarin had been 
determined in test Samples, a comparison was made between 
the accuracy of these values and the errors that had been 
anticipated due to the dissociation of bound warfarin during 
Such measurements. For instance, the differences in the 
measured and predicted free fractions in Table 2 (+18% for 
R-warfarin and -16% for S-warfarin) were much smaller 
than the errors of 20-40% that were expected from FIG. 4 
and related plots at comparable extraction times. It was 
Suspected from this that these earlier graphs had overesti 
mated the role played by dissociation effects during the 
isolation of free drug fractions by immunoaffinity chroma 
tography. 
A more complete picture of the immunoaffinity extraction 
proceSS was obtained through the use of computer Simula 
tions. This was accomplished by developing a model which 
no longer made the same assumptions that were used in FIG. 
4. For instance, this model allowed the free and dissociated 
warfarin to undergo a continuous (rather than instantaneous) 
extraction on the immunoaffinity microcolumn. It was also 
now possible to consider the use of a column with a finite 
binding capacity and Samples in which any non-complexed 
warfarin could bind to HSA instead of the immobilized 
antibodies. This was accomplished by adapting a previous 
algorithm that has been used to study the adsorption of 
analytes to affinity supports, (Hage, D. S.; Walters, R. R. J. 
Chromatogr: 1988, 436, 111; Rollag, J. G.; Hage, D. S. J. 
Chromatogr: A 1998, 795, 185; and Hage, D. S.; Thomas, D. 
H.; Roy Chowdhuri, A.; Clarke, W. Anal. Chem. 1999, 71, 
2965.) with the inclusion of a reversible solution-phase 
reaction between the injected drug and its binding proteins. 
Further details on this approach can be found in the Methods 
and Materials. 
FIG. 8 shows the simulation results that were obtained for 
R-warfarin. Similar plots were generated for S-warfarin. The 
Sample and column conditions that were used in these 
Simulations were the same as those that were present in the 
experimental determination of the free warfarin fractions. 
The rate constant for adsorption of warfarin to the immo 
bilized antibodies was estimated from the earlier studies that 
examined the extraction of R- and S-warfarin by the immu 
noaffinity column. 
The lower plot in FIG. 8 shows how the extraction 
efficiency of warfarin was predicted to change as this drug 
was injected at various flow rates. This extraction had its 
highest efficiency at low flow rates and a decreasing effi 
ciency at higher flow rates. This occurs because there is a 
Smaller contact time between the Sample and the immobi 
lized antibodies as higher application flow rates are used. 
The top plot in FIG. 8 shows how the relative concentra 
tion of extracted warfarin compared to the true free fraction 
in warfarin/HSA mixtures when the bound warfarin in these 
Samples was allowed to undergo dissociation and rebinding 
to the HSA. As expected, higher flow rates and shorter 
column residence times resulted in less dissociation effects. 











(free plus dissociated warfarin) to approach the concentra 
tion of free warfarin that was actually removed from the 
Sample. 
One observation that can be made by comparing the two 
plots in FIG. 8 is that there will be an optimum flow rate 
range over which the best estimates can be made of a drug's 
true free fraction. For instance, FIG. 8 shows that the extent 
of warfarin dissociation from HSA will be minimized by 
operating at high flow rates; however, this decreases extrac 
tion of the free warfarin fraction. Working at slower flow 
rates provides a better extraction efficiency but suffers from 
greater errors due to bound drug dissociation. It is only at 
intermediate flow rates that a balance is obtained between 
accuracy and extraction recovery. In this particular case, it 
was predicted that a flow rate range of roughly 0.9-1.6 
mL/min was needed to obtain an error of +15% or less in the 
measured free fractions. This compares well with the 
approximate errors of +18% and -16% that were estimated 
for R- and S-warfarin under these flow rate conditions. 
Another observation that can be made from FIG. 8 is that 
the free fraction errors predicted by the Simulations were 
less than those that were originally estimated through the use 
of Simple drug-protein dissociation. For instance, it was 
determined from FIG. 4 that dissociation of S-warfarin from 
HSA would increase the measured free fraction of this drug 
by 25-30% at an extraction time of 180 ms. However, the 
more complete model used in the Simulations indicated that 
a maximum error of only 15% would be expected. 
In light of the detailed description of the invention and the 
examples presented above, it can be appreciated that the 
Several aspects of the invention are achieved. 
It is to be understood that the present invention has been 
described in detail by way of illustration and example in 
order to acquaint otherS Skilled in the art with the invention, 
its principles, and its practical application. Particular for 
mulations and processes of the present invention are not 
limited to the descriptions of the Specific embodiments 
presented, but rather the descriptions and examples should 
be viewed in terms of the claims that follow and their 
equivalents. While Some of the examples and descriptions 
above include Some conclusions about the way the invention 
may function, the inventor does not intend to be bound by 
those conclusions and functions, but puts them forth only as 
possible explanations. 
It is to be further understood that the specific embodi 
ments of the present invention as Set forth are not intended 
as being exhaustive or limiting of the invention, and that 
many alternatives, modifications, and variations will be 
apparent to those of ordinary skill in the art in light of the 
foregoing examples and detailed description. Accordingly, 
this invention is intended to embrace all Such alternatives, 
modifications, and variations that fall within the Spirit and 
Scope of the following claims. 
What is claimed is: 
1. A method to determine the concentration of a free 
analyte fraction in a Sample, the Sample comprising a 
biological fluid having a bound analyte fraction and the free 
analyte fraction, the method comprising: 
(a) applying, the sample to an affinity column having an 
active layer which Selectively binds free analyte rela 
tive to bound analyte wherein the active layer Separates 
the free analyte fraction from the bound analyte frac 
tion of the Sample in the millisecond time domain; 
(b) detection of signal from the free analyte fraction 
Separated from the Sample, and 
(c) determining the concentration of free analyte present 
in the Sample. 
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2. The method of claim 1 wherein the affinity column 
comprises an active layer, the active layer comprising Sup 
port particles derivatized with a binding agent. 
3. The method of claim 2 wherein the active layer is from 
about 10 microns to about 1.1 millimeters in length. 
4. The method of claim 2 wherein the active layer is not 
less than 60 microns in length. 
5. The method of claim 2 wherein the binding agent is 
Selected from the group of agents consisting of antibodies, 
aptamers, antibody fragments, Synthetic molecular imprints, 
antibody related molecules and recombinant proteins. 
6. The method of claim 5 wherein the binding agent is 
antibodies. 
7. The method of claim 6 wherein the binding agent has 
a high binding affinity for the free analyte fraction. 
8. The method of claim 7 wherein the binding agent has 
a binding affinity for the free analyte fraction from about 10 
to about 10 M. 
9. The method of claim 7 wherein the binding agent has 
a binding affinity for the free analyte fraction greater than 
about 10 M'. 
10. The method of claim 7 wherein the free analyte 
fraction is separated from the Sample from about 1 to about 
500 milliseconds after injection of the sample into the 
microcolumn. 
11. The method of claim 10 wherein the free analyte 
fraction is separated from the Sample from about 1 to about 
100 milliseconds after injection of the sample into the 
microcolumn. 
12. The method of claim 10 wherein the signal is detected 
from the free analyte fraction by an off-line method or an 
on-line method. 
13. The method of claim 12 wherein the signal is detected 
by an on-line method with direct detection. 
14. The method of claim 12 wherein the signal is detected 
by a method Selected from the group consisting of 
immunoassay, mass spectrometry, gas chromatography, 
ultraViolet absorbance, fluorescence detectors, and electro 
chemical detectors. 
15. A method to determine the concentration of a free 
analyte fraction in a Sample, the Sample comprising a bound 








(a) applying the sample to an affinity column wherein the 
column Separates the free analyte fraction from the 
Sample in the millisecond time domain; 
(b) detection of signal from the free analyte fraction 
Separated from the Sample, and 
(c) comparing the Signal detected in (b) to a standard 
thereby determining the concentration of free analyte 
present in the Sample. 
16. The method of claim 12 wherein the active layer is 
introduced by a plurality of injections. 
17. The method of claim 16 wherein the active layer is 
introduced by about 10 to about 100 injections. 
18. The method of claim 17 wherein the active layer is 
introduced by about 30 to about 40 injections when the 
active layer is from about 100 to about 500 microns in 
length. 
19. The method of claim 17 wherein the active layer is 
introduced by about 60 to about 80 injections when the 
active layer is from about 60 to about 100 microns in length. 
20. The method of claim 17 wherein the support particles 
comprising the active layer are injected onto the column at 
a density of from about 0.1 to about 20 milligrams of support 
particle per milliliter of packing Solvent. 
21. The method of claim 16 wherein the biological fluid 
is Selected from the group consisting of blood, plasma, urine, 
cerebroSpinal fluid, a tissue Sample, and intracellular fluid. 
22. The method of claim 21 wherein the binding capacity 
of the active layer comprises a ratio of the number of active 
binding sites to amount of free analyte present in the Sample 
between about 1:1 to about 10:1. 
23. The method of claim 22 wherein the sample is injected 
onto the column at a flow rate of about 0.01 to about 9.0 
milliliters per minute. 
24. The method of claim 23 wherein the sample is injected 
onto the column at a pressure of about 100 to about 1500 psi. 
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